Source: Annual Congress 2001 - Infection in the ICU
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. Dudzevicius, R. Sakalauskas, I. Stankeviciene, K. Malakauskas (Kaunas, Lithuania). Previous antibacterial therapy and drug-resistance among pathogens in ICU patients with nosocomial pneumonia. Eur Respir J 2001; 16: Suppl. 31, 2752

Member's Comments

No comment yet.

Related content which might interest you: The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Analysis of antibiotic resistance and enterococcal infections of low respiratory infection on patients in hospital Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Antibiotic management of nosocomial pneumonia in children Source: Eur Respir J 2006; 28: Suppl. 50, 633s Year: 2006 The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006 Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007